biostudies-literatureUnknown14(4)Sekai ISystemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after enClinical journal of gastroenterology1191-1196https://www.ebi.ac.uk/biostudies/studies/S-EPMC8298218biostudies-literatureA case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells.PMC8298218Watanabe TKudo MSekai IHagiwara SfalseA case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells.Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after en2021-01-01T00:00:00Z2021 Aug2025-04-04T09:30:29.852Z2022-02-10T21:48:57.22ZS-EPMC82982183366568910.1007/s12328-020-01317-y